News & Events

Published On: 3/17/2020

TARGET PharmaSolutions Expands TARGET-DERM Research Community with Two New Industry Partnerships

Real-world clinical data company, TARGET PharmaSolutions Inc., announced today new partnerships with two multinational pharmaceutical corporations to support the TARGET-DERM observational study. They join current partner Novartis in support of this collaboration to evaluate adult and pediatric patients with atopic dermatitis (eczema) and other immune-mediated inflammatory skin conditions.

“The two new collaborative industry partnerships are evidence that TARGET’s real-world data is extremely valuable to the dermatology community,” said TARGET PharmaSolutions CEO, Neal Bibeau. “These companies join TARGET in our commitment to improving patient lives, and we are thrilled to play a key role in helping to inform their future direction with a base of strong scientific evidence.”

TARGET’s real-world database enrolls consented patients across a variety of community and academic sites to collect the structured and unstructured medical record data needed to inform optimal and individual treatment approaches. The real-world data can be utilized throughout the pharmaceutical development and commercialization process.

“The longitudinal, real-world data that TARGET-DERM is collecting will help to shape understanding of the natural history of atopic dermatitis,” said TARGET-DERM Steering Committee Co-Chair, Emma Guttman-Yassky, MD, PhD, professor and vice chair for research in the Department of Dermatology at the Icahn School of Medicine at Mount Sinai Medical Center. “It will also capture important treatment safety and effectiveness of new agents across populations as they come to market.”

Launched in 2019, TARGET-DERM is the sixth disease community created by TARGET since 2015. The first disease community launched by the company, TARGET-NASH, is currently in its fourth year of data collection. Other ongoing TARGET studies include hepatocellular carcinoma (HCC), inflammatory bowel disease (IBD), primary biliary cholangitis (PBC) and chronic hepatitis B (HBV). TARGET-ASTHMA is the newest community developed.

To create each real-world community, the TARGET model organizes groups of stakeholders around specific diseases to produce regulatory-grade data and analysis on the disease’s natural history, current treatment paradigms, and patient outcomes. This includes key scientific leaders, regulatory agencies, pharmaceutical manufacturers, and patient advocacy groups who are responsible in answering strategic questions and determining the study’s structure.

About Target RWE

As the industry's best-in-class, complete real world evidence (RWE) solution, Target RWE is a distinctly collaborative enterprise that unifies real world data (RWD) sets and advanced RWE analytics in an integrated community, shifting the paradigm in healthcare for how decisions are made to improve lives.

Target RWE sources unique, connected data sets across multiple therapeutic areas representing granular data from diverse patients in academic and community settings. Our rigorous, interactive, and advanced RWE analytics extract deep insights from RWD to answer important questions in healthcare. Target RWE brings together the brightest minds in healthcare through an unmatched community of key opinion leaders, patients, and healthcare stakeholders in a collaborative and dynamic model.


Kayla Slake
Marketing Manager

984.234.0268 ext 205